Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is increasingly used by the general population, intending to enhance their cognitive function. In this literature review, we aim to answer whether this is effective. We present a novel way to determine the extent to which MPH enhances cognitive performance in a certain domain. Namely, we quantify this by a percentage that reflects the number of studies showing performance enhancing effects of MPH. To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively. The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65% of included studies) and speed of processing (48%), and to a lesser extent may also improve verbal learning and memory (31%), attention and vigilance (29%) and reasoning and problem solving (18%), but does not have an effect on visual learning and memory. MPH effects are dose-dependent and the dose-response relationship differs between cognitive domains. MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses its benefits in relation to the risks specific to this drug.
Introduction
Methylphenidate (MPH; see Table 1 for a complete list of abbreviations) is a stimulant drug that is mainly prescribed in attention deficit hyperactivity disorder (ADHD, (Leonard et al., 2004) ). In the past decades there has been a vast increase in the use of MPH (Diller, 1996) . Not only by patients to whom MPH is prescribed, but also by the general population, who believe that MPH enhances their cognitive functions (Maher, 2008) . This has raised ethical concern (Sahakian and Morein-Zamir, 2007; Larriviere et al., 2009; Stix, 2009) . Discussions in popular scientific literature consider safety, potential abuse and side effects Stix, 2009 ) of cognition-enhancing drugs. However, even if these issues were no reason for concern, a critical question would still be: 'How effective are supposed cognition-enhancing drugs actually?'. Although there are some indications that MPH may improve certain aspects of cognitive function (e.g. working memory (Mehta et al., 2000b) ), there are also reports of impaired performance on cognitive tasks after MPH (e.g. planning (Elliott et al., 1997) ). While a reasonable amount of studies have examined cognitive effects of MPH in healthy volunteers, the evidence is undeniably mixed.
Cognitive effects of MPH in children with ADHD have been reviewed by Pietrzak et al. (2006) . Their extensive review includes evidence on a broad range of cognitive functions and presents it classified into several cognitive domains. An equivalent review on cognitive effects of MPH in healthy volunteers is not available yet. Previous reviews on the cognition-enhancing effects of drugs have focused on attention, learning, memory and executive function (Repantis et al., 2010; Smith and Farah, 2011 ). In the current review the full spectrum of cognitive function is considered. The differences between studies on cognitive effects of MPH -such as differences in methodology, MPH dose, neuropsychological instruments employed -do not encourage conducting a meta-analysis (Pietrzak et al., 2006) . As we did not want to limit our review to one particular measure or cognitive domain, we used a similar approach as Pietrzak et al. (2006) . Because the review by Pietrzak et al. (2006) focused on studies involving children with ADHD, the reported tasks differ slightly from those in studies with healthy volunteers, since both clinical status (i.e. ADHD diagnosis) and age (children vs. adults) may call for a different selection of tasks. Inspection of the range of tasks used in studies with MPH in healthy volunteers, and the fact that the classification applied by Pietrzak et al. (2006) is not based on factor analysis or any other established way of classifying cognitive tasks (or this is not reported), we looked for a classification that was more appropriate for the available data (Pietrzak et al., 2006) .
The categorization described by Nuechterlein et al. (2004) is based on factor analytic studies and fine-tuned by a committee of field experts. Although the identification considered cognitive function in schizophrenia patients, it is generally accepted that cognitive domains are broadly the same in healthy controls (Dickinson et al., 2006; Genderson et al., 2007 ). The cognitive domains (i.e. speed of processing, attention/vigilance, working memory, verbal learning and memory, visual learning memory and reasoning and problem solving) fit well with the literature on healthy volunteers and are employed in this review (Nuechterlein et al., 2004) .
Considering the mixed nature of the literature, a descriptive statistic quantifying the evidence would facilitate its interpretation. Pietrzak et al. (2006) summarize the results within each domain as a percentage of studies reporting cognition enhancing effects of MPH. In order to also take into account factors that determine the statistical power of the studies (number of participants and number of tasks/measures), we established a weighed percentage reflecting the relative contribution of the studies reviewed to the MPH effects (Kleijnen et al., 1991) .
Effects of dopamine on cognition are often described to follow an inverted-U-shaped curve in which intermediate levels of neurotransmitter activity lead to optimal cognitive performance, but lower and higher levels may lead to suboptimal performance (Husain and Mehta, 2011) . Since MPH blocks the dopamine and noradrenaline transporters, thereby blocking reuptake of these neurotransmitters, MPH leads to increased levels of dopamine and noradrenaline availability (Volkow et al., 1998; Hannestad et al., 2010) and may demonstrate inverted-U properties. Moreover, dose-response relationships may vary between cognitive domains. Therefore, we report a weighed percentage reflecting MPH effects, equivalent to the one described above for low, medium and high doses, respectively.
The aim of this review is to answer the question whether MPH can enhance cognitive function in healthy individuals. This review specifically looks at the acute effects of MPH on healthy adults (i.e. excluding effects of other medications, effects on children, effects after sleep deprivation and long term effects). Effects on the elderly are discussed in a separate paragraph, as well as imaging data.
Method

Literature search
A literature search was performed in PubMed and Psychinfo using the search term Methylphenidate combined with the terms cognition, neuropsychology, executive, working memory, vigilance and inhibition in separate searches. Reference lists of extracted articles were screened for omissions in our search. Studies that were included fulfilled the following criteria: used immediate release formulation of MPH; assessed the effects of acute doses of MPH; assessed healthy human adults 18 yr and older; assessed the effects using cognitive tasks; were written in English; published in a peer-reviewed journal. Both studies employing a within-and between-subjects design were included. Studies assessing chronic or subchronic effects of MPH were not included. The earliest study included was published March 1978 and the last included study was published May 2013.
Categorization
The neuropsychological tests were categorized into six different cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning and memory, visual learning and memory and reasoning and problem solving (Nuechterlein et al., 2004) . Tasks employed in the included articles were categorized following the classification by Nuechterlein et al. (2004) . If more than one cognitive domain was applicable, tasks were still classified as measuring one domain only (i.e. the most salient domain). Tasks that could not be categorized in any of these six cognitive domains were not included in the analysis (for instance 'spatial bias' in (Dodds et al., 2008a) ).
Outcome measure
For each domain a weighed percentage was calculated reflecting to what extent MPH affects task performance in that specific domain. It was calculated as follows:
Outcome measure = ( (number of participants × outcome significance testing × relative contribution)) ( (number of participants × relative contribution)) × 100% in which number of participants was used as reported for within-subjects designs, while for between-subjects designs, the number of participants that received MPH was used in the calculation. Outcome significance testing was defined as: 1 = significantly improved task performance; −1 = significantly impaired task performance; 0 = no significant effect; 0.5 = trend towards improved task performance; −0.5 = trend towards impaired task performance, and the factor to correct for multiple comparisons (relative contribution) was defined as: 1/number of tasks or measures within the study that are reported in Table 2 (i.e. if three measures were reported in the article, but only two were listed in Table 2 ., the factor was 1/2 = 0.5). Only data of participants aged between 18 and 60 were included in the calculation. Data on elderly participants are discussed in a separate paragraph.
Another frequently considered evaluation parameter is effect size, and it would be interesting to compare this to our study evaluation measure. However, due to the fact that most of the reported studies did not convey all essential information necessary to calculate it, effect sizes were not reported.
Dose effects
The outcome measure as detailed above was also calculated for low, medium and high doses separately. A low, medium or high dose was defined as follows: low: 410 mg or 40.15 mg/kg; medium: >10 mg, 420 mg or >0.15 mg/kg, 40.3 mg/kg; high: >20 mg or >0.3 mg/kg. If it was not clearly stated which dose(s) led to significant effects, it was assumed that the reported effect was applicable to every administered dose.
Results and discussion
In total 60 studies met the inclusion criteria. Of these, 56 included healthy volunteers between 18 and 60 yr old. All studies are listed in Table 2 . The extent to which MPH enhances cognitive performance (quantified by a weighed percentage) is reported in Table 3 . The results show that MPH most effectively enhances performance in the domain of working memory. Second most affected were tasks measuring speed of processing, followed by verbal learning and memory, attention/vigilance, reasoning and problem solving, and visual learning and memory. In the next few paragraphs, the results per domain are discussed in more detail.
Working memory
Working memory involves the temporary storage and manipulation of information (Baddeley, 1992) . For the purpose of this review, no distinction was made between short term memory and working memory tasks. A common working memory task is the digit span, requiring subjects to repeat a sequence of digits either in the exact same or reversed order. More complex tasks include memory scanning tasks and N-back tasks. Memory scanning tasks present participants with probes that they have to compare to a memory set that may vary in size, and hence, memory load (Sternberg, 1966) . N-back tasks require a response to stimuli that are the same as the stimulus that was presented N-trials before. Other tasks specifically assess spatial working memory, which is often associated with dopaminergic activity . Although the number of MPH studies including a test of working memory was not very high, the proportion that shows enhancing effects in this cognitive domain was the highest of all reported domains, namely 65%.
The proportion of the effect of MPH was similar across different types of tasks. The highest proportion of significant effects was observed with the medium dose. This was also reflected by a subset of tests, namely the spatial working memory tests. It is possible that the MPH-effect follows an inverted-U-shaped curve as a function of dose, since a high dose (60 mg) exerted no effect on a spatial working memory task that was affected by lower doses in other studies ( (Elliott et al., 1997; Mehta et al., 2000b; Clatworthy et al., 2009 ), but note that Elliott et al. (1997) found no main effects).
Speed of processing
Tasks that are classified as a measure of speed of processing are relatively simple, involving fundamental processes such as perception and motor action. This category includes, for example, digit symbol substitution tests (DSST) and trail making tests (TMT); version A and B
The speed of processing domain was, with 48%, the second most affected domain in terms of performance enhancing effects of MPH. This is consistent with the notion that MPH speeds up response time in healthy volunteers (Elliott et al., 1997) , reflecting response-readiness enhancing effects (Linssen et al., 2011) .
A striking observation is that the low dose exerted the highest proportion of effects on cognitive performance in this domain, followed by the medium dose, with the highest dose showing the lowest proportion of effects. This suggests that within this domain the optimal dose is rather low and the higher the dose, the less healthy volunteers benefit from it.
Verbal learning and memory
Whereas MPH affected the former two domains in 48% or more of the reported measurements, the domain of verbal learning and memory was somewhat less affected. A proportion of 31% of the studies showed enhanced performance in this domain after administration of MPH. The cognitive domain of verbal learning and memory typically refers to declarative memory tasks such as word learning tests, verbal paired associates learning (PAL) and story recall. Verbal PAL tasks involve learning pairs of stimuli (words or letters) and recalling the corresponding member of the pair upon presentation of probe stimuli. Positive effects of MPH on declarative memory fit well with accounts of related stimulant drugs affecting word list learning (Soetens et al., 1993 (Soetens et al., , 1995 Zeeuws and Soetens, 2007) . The relationship between MPH dose and its effect on word list learning seems to be a positive and linear one. This contrasts with the striking finding that a high MPH dose can decrease performance on a PAL task and story recall. Across the domain of verbal learning and memory the low and medium doses exert more cognition enhancing effects than high doses. Hence, even within one domain, different dose-response relationships may be observed for different tasks.
Attention/vigilance
As William James stated in 1890, 'everyone knows what attention is' (James, 1890) . It is, however, difficult to give a clear and inclusive definition. It involves filtering information, focusing on certain aspects of what is perceived, while disregarding others. Many different forms of attention are distinguished (e.g. sustained attention, focused attention, divided attention). In this review, however, a collective domain 'attention and vigilance' is employed.
Based on previous literature, associating attention with dopaminergic activity (Nieoullon, 2002; Nieoullon and Coquerel, 2003; Cools and Robbins, 2004) , it was expected that the domain of attention/vigilance would be one of the most affected by MPH. However, with 29%, this domain was only the fourth most affected. A possibly confounding factor might be that tasks from the attention/vigilance domain are often included in MPH studies as control measures because they are thought to be sensitive to MPH effects. Indeed, this domain was assessed most frequently of all domains (87 measures across 27 studies). Furthermore, the tasks within this domain were often split into multiple measures, which may affect the final outcome.
Reasoning and problem solving
The next cognitive domain involves planning and decision making, aspects of cognition that are usually referred to as executive functioning. However, in order to allow a separate category on working memory, which is often included in executive functioning, this domain is named reasoning and problem solving. A typical task in this domain is the Tower of London, in which balls (Wetzel et al., 1981) Overall, 18% of the results reflected improved performance within this domain after MPH. The reported results suggested that improvement of performance occurs more frequently with a higher dose.
Visual learning and memory
The last cognitive domain to discuss is visual learning and memory. Tasks classified as assessing performance in this cognitive domain are, for example, picture recognition tests and other learning and memory tasks involving visual stimuli. None of the studies found an effect of MPH on visual learning and memory (Wetzel et al., 1981; Bullmore et al., 2003; Brignell and Curran, 2006; Kuypers and Ramaekers, 2007; Dodds et al., 2008b; Clatworthy et al., 2009; Finke et al., 2010) . It is, however, important to note that the data reported within this domain only comprises eight measures across six studies. This gives the conclusion regarding the absence of an MPH effect on visual learning and memory somewhat less weight.
Imaging studies on cognitive performance under the influence of MPH
Of the studies included in this review, 26 studies obtained imaging data during cognitive testing. In 14 of these studies electroencephalography (EEG) measures were taken. Furthermore, there were seven studies with functional magnetic resonance imaging (fMRI) data, three with positron emission tomography (PET) data, one with transcranial magnetic stimulation (TMS) data and one with functional near-infrared spectroscopy (fNIRS) data.
The EEG data are summarized in Table 4 . Components often assessed during attention, working memory or 9,12,16,22,24,25,33,36,37,38,43,45,53, 11, 17, 22, 23, 25, 26, 30, 33, 35, 39, 42, 48, 49 2, 3, 6, 13, 14, 15, 17, 18, 19, 22, 25, 26, 27, 28, 31, 36, 41, 43, 44, 45, 46, 47, 52, 54, 55 (Brumaghim et al., 1987) P3b SMS WM Shorter P3b latency (Callaway, 1984) P3b SERS SoP No effect (Coons et al., 1981) LPC, CNV CPT, Oddball, Choice RT A/V, SoP Increased LPC in CPT, increased CNV in choice RT (Cooper et al., 2005) N1, P2, N2 and P3 CPT A/V Shorter P3b latency, increased P3b amplitude (Fitzpatrick et al., 1988) P3b Memory scanning task WM No effect (Hermens et al., 2007) N1, P2, N2 and P3 Oddball, CPT A/V No effect (Hink et al., 1978) N1, P2 and P3 Target detection task A/V No effect Linssen et al. (2011) CNV CNV task SoP Increased CNV amplitude (Naylor et al., 1985) P3 SERS SoP No effect (Oken et al., 1995) Event-related desynchronization Visual search tasks A/V No effect (Strauss et al., 1984) P2, P3a, P3b CPT, PAL A/V Shorter P3b latency, increased P3b amplitude for CPT (Studer et al., 2010) P3, slow waves Serial visual WM task WM No effect * Task during which the imaging data were acquired.
speed of processing tasks include N1, P2, N2 and P3 ERP components. While the former two components, N1 and P2, are thought to reflect perceptual processes such as orienting and directing of attention, the N2 and P3 are cognitive components reflecting allocation of attentional resources and stimulus evaluation (Anderer et al., 2002) . The studies reviewed found no effects of MPH on the earlier components, while increased P3 source strength, increased P3b amplitude and shorter P3b latency were observed in several studies (Coons et al., 1981; Strauss et al., 1984; Anderer et al., 2002; Cooper et al., 2005) . This is thought to reflect an MPH-induced enhancement of attentional processes or increased recruitment of attentional resources. Other studies did not report an effect of MPH on P3 (Hink et al., 1978; Callaway, 1984; Naylor et al., 1985; Fitzpatrick et al., 1988; Hermens et al., 2007; Studer et al., 2010 ). An explanation offered for these findings is that MPH affects response processing, as reflected by faster responses, but that MPH does not speed stimulus evaluation processing. Another component assessed in the studies listed in Table 4 was the Contingent Negative Variation (CNV). MPH was observed to enhance CNV amplitude, reflecting increased response readiness (Coons et al., 1981; Linssen et al., 2011) . Event-related desynchronization, measured during a visual search task, was not affected by MPH (Oken et al., 1995) .
Of the seven studies in this review that acquired fMRI data, three studies assessed brain activity during response inhibition tasks, i.e. Go/No-go and stop signal (Hester et al., 2012; Pauls et al., 2012; Costa et al., 2013) . Hester et al. (2012) observed that activation of the dorsal anterior cingulated cortex and the inferior parietal lobe differed between errors of which the participants were aware vs. unaware in a Go/No-go task. MPH increased these differences in activation of the dorsal anterior cingulate cortex and the inferior parietal lobe. This is suggestive of the underlying mechanism leading to improved response inhibition with MPH. Pauls et al. (2012) suggest that inhibition effects are mediated through MPH effects on the attentional mechanisms. Pauls et al. (2012) reported reduced activation of different regions that are associated with the ventral attention system, i.e. the right inferior frontal gyrus and insula, during various types of infrequent stimuli. Costa et al. (2013) showed that MPH increased activity in the putamen during error of inhibition but not during successful inhibition in the Go/No-go task, while no such effect was observed in the stop signal task. This effect may be due to saliency of errors in the Go/No-go task, suggesting that MPH interacts with saliency.
Two fMRI studies on working memory showed increased activation of the dorsal attention network and altered default mode network activation with MPH (Marquand et al., 2011; Tomasi et al., 2011) , suggesting that MPH may exert its effects on cognition partly by modulating the default mode network.
During a probabilistic reversal learning task MPH decreased activation in the ventral striatum during response switching, while activation changed in the prefrontal cortex if there was no switching of response. MPH reduced dorsal anterior cingulate cortex activation during errors on a stroop task (Moeller et al., 2012) .
Among the imaging studies were three PET studies. One PET study revealed that MPH reduced the amount of glucose used by the brain during cognitive task performance (Dodds et al., 2008b) . This is thought to reflect focusing of attention. MPH was also shown to reduce regional cerebral blood flow in the dorsolateral prefrontal cortex and posterior parietal cortex during MPH-induced improved performance of a working memory task (Mehta et al., 2000b) . Finally, MPH-induced enhancement of cognitive performance could be predicted by its effect on dopamine receptor availability, as measured with PET (Clatworthy et al., 2009) .
Using TMS, MPH was shown to alter motor system excitability in a response inhibition task (Kratz et al., 2009) , suggesting MPH can fine-tune the motor system. Finally, a study employing fNIRS reported decreased oxyhemoglobin concentration with MPH compared to placebo in the right frontal lobe, consistent with the PET finding by Mehta et al. (2000) described above.
In sum, the imaging studies on cognitive performance under the influence of MPH show that MPH enhances attentional processing and modulates activity in brain areas associated with inhibition and attention. However, more studies are needed to draw more exact conclusions, as existing studies vary widely with respect to task, method and peak/area of interest.
Cognitive effects of MPH in the elderly
A limited number of studies investigated the effects of MPH on cognition in the elderly (Callaway, 1984; Turner et al., 2003; Muller et al., 2005; Ben-Itzhak et al., 2008; Izquierdo et al., 2008; Drijgers et al., 2012) . The effect of MPH on working memory performance was tested in an extensive study by Turner et al. (2003) by means of a digit span task, a spatial working memory task and a spatial span task. None of the tasks was significantly affected by MPH.
Speed of processing was also not affected as measured with a SERS task in the study of Callaway (1984) and letter digit substitution and simple and choice reaction time tasks in the study by Drijgers et al. (2012) . The four-choice motor reaction task employed by Muller et al. (2005) , showed a performance enhancing effect of MPH on a difficult version of the task. In this uncued version, participants were asked to move a joystick towards a stimulus that was presented in an uncued location. Performance on the cued version of the task was impaired by MPH.
Effects of MPH on verbal learning and memory was assessed by Izquierdo (2008) with tests of formal and incidental memory in which memory of, respectively, unintentionally remembered an intentionally remembered information was tested. MPH was shown to reverse age-related decline of persistence of incidental memory. No such effect was observed for formal memory.
Reasoning and problem solving, as measured with a Tower of London task, did not reveal any effects of MPH on older adults' performance.
Effects of MPH on older adults' attention and vigilance task performance was tested in four different tasks i.e. RVIP task; ID/ED shift task; stop signal task (Turner et al., 2003) ; Go/No-go task (Ben-Itzhak et al., 2008) . Performance of the RVIP and stop signal tasks was not affected by MPH. In the ID/ED task a significant slowing of responses similar to that in young volunteers was observed. However, this was not accompanied by an improvement in accuracy, as is the case in young volunteers. In the Go/No-go task, on the other hand, accuracy improved under the influence of MPH, while response time was not affected.
Within the domain of visual learning and memory, two tests were administered, i.e. a non-verbal PAL test and a test of nonverbal memory in which memory of the spatial orientation of geometric objects is tested with a recognition test (Ben-Itzhak et al., 2008) . Performance of neither of these tasks by older adults was affected by MPH.
In sum, MPH does not improve working memory, reasoning and problem solving and visual learning and memory in older adults. Some effects were observed within the domains of speed of processing, verbal learning and memory and attention and vigilance. These results only partly parallel those in younger volunteers, with the main difference being the lack of effects on working memory in older adults. However, the limited number of studies in older adults limits the conclusions that can be drawn from these data.
Adverse effects and ethical issues
While we cannot speak of a global cognition enhancing effect of MPH, the research reviewed in this paper shows that MPH can improve working memory and speed of processing and, to a lesser extent, verbal learning and memory, reasoning and problem solving and attention and vigilance in healthy volunteers. Reports of cognition enhancing effects of MPH might encourage such use. We would, therefore, like to put our findings in perspective and discuss adverse effects of MPH and related ethical issues.
The effectiveness of MPH as cognitive enhancer should not be overestimated (Ragan et al., 2013) . All experimental studies reviewed here reflect effects in relatively homogeneous groups assessed in controlled environments using sensitive tests. In daily life, circumstances are much more diverse and complex, which makes it hard to verify the enhancing effects of MPH on performance in authentic situations. Any such effect is likely to be relatively small in comparison to the effects of adequate sleep, education and work-life balance, and will be subject to individual differences.
Even if MPH substantially improved real-life performances, the question remains whether the benefits outweigh the risks. Common adverse effects of chronic MPH use include insomnia, nervousness, irritability, anxiety, jitteriness, increased heart rate, dizziness, drowsiness, headache, stomach ache, anorexia and appetite suppression (Diller, 1996; Klein-Schwartz, 2002; Repantis et al., 2010) . Large doses of MPH can lead to psychosis, seizures and cardiovascular events (Lakhan and Kirchgessner, 2012) . Cardiovascular effects associated with ADHD stimulant medications include hypertension and tachycardia (Lakhan and Kirchgessner, 2012) .
Another risk related to MPH use is the potential abuse of the drug. When MPH is used appropriately for ADHD there is little evidence of addiction and/or abuse of MPH (Diller, 1996) . However, MPH can have reinforcing effects through its effects on dopamine in the brain (Volkow et al., 1999) . Reinforcing effects depend on the rate of uptake of the drug (Volkow et al., 2002; Leonard et al., 2004) , which explains why people who use MPH to induce a high administer it intravenously or intranasally, while people who merely take it to stay awake, take it orally (Klein-Schwartz, 2002; Volkow and Swanson, 2003) . Self-administration of MPH is likely limited by the low rate of clearance of MPH from the brain, in which it differs from cocaine (Volkow et al., 1995) .
MPH use without prescription could be dangerous for various reasons. Individual risks of which users may not be aware, such as interaction with other medicinal drugs or abnormalities in the cardiovascular system, cannot be monitored by a physician if MPH is obtained otherwise (Sahakian and Morein-Zamir, 2007) . If users purchase the pills online it might not actually be MPH, which may create additional unknown risks (Ragan et al., 2013) . This may be a motive to regulate off-label stimulant use (Sahakian and Morein-Zamir, 2007) . However, making MPH or other medications easily and legally available can lead to other problems with coercion to take such drugs (for example, in specific military or medical professions or in children) and fairness (if only rich people can afford to buy such drugs).
Attitudes towards cognitive enhancement vary between authors: while some are generally positive and optimistic and mainly call for guidelines (Sahakian and Morein-Zamir, 2007; Greely et al., 2008) , others are more conservative (Ragan et al., 2013) or even consider the current debate to be a 'bubble' or 'media hype' and merely stress that the evidence for increased stimulant use is weak. However, everyone agrees that more research is needed, whether it is to obtain accurate prevalence rates or to increase our knowledge about the benefits and harm of cognition enhancing drug use in healthy individuals. We would like to add one recommendation to the existing abundance of recommendations: research and reviews of research on cognition-enhancing drugs should preferably address one single drug at a time. 'Cognition-enhancing drugs' are often described as if there were a group of virtually identical drugs with similar effectiveness and side effect profiles. It is very important to study specific, individual features of a drug, as it is essential to study a drug's effectiveness in relation to its side effects and other potential risks. Any description of a group of drugs is likely to be a generalization and may lead to over-or under-estimation of risks and benefits.
Conclusions
In this review the performance enhancing effect of MPH within various cognitive domains was quantified by a percentage (weighed on the basis of specified criteria such as number of subjects). This is a major improvement compared to earlier reviews in which only some domains of cognition were considered, the categorization in domains was less well specified (Repantis et al., 2010; Smith and Farah, 2011) and/or the quality was either not taken into account or based on criteria that hardly differentiate between studies (e.g. double blind design, randomization (Jadad et al., 1996) ). Furthermore, this review compares 59 studies, which is considerably more than in previous reviews. The studies reviewed show that MPH improves cognitive performance in the healthy population in the domains of working memory and speed of processing, and to a lesser extent may also improve verbal learning and memory, attention and vigilance and reasoning and problem solving, but not visual learning and memory (see Table 3 ).
There were quite large differences between the domains with respect to the cognition enhancing effect of MPH, the lowest percentage being 0% and the highest 65%. These differences confirm that in studying cognitive performance it is important to distinguish between different domains of cognitive function. MPH may not globally improve cognitive performance, but it has potential to enhance certain aspects of cognitive performance at certain doses.
The dose-response relationship of the cognition modulating effect of MPH differs across different cognitive domains. In some domains, low doses are more effective than high doses. An explanation for this may be that, in healthy volunteers, dopamine availability is already close to the optimal level. Enhancing dopamine activity may push the level of dopamine beyond the optimum without improving performance, or even leading to suboptimal performance.
Factors limiting the conclusions in this review relate to the decisions that were made on how to categorize, list and present the data. Tasks not described by Nuechterlein et al. (2004) were categorized by the authors. Other decisions that were well thought through, but might still be somewhat arbitrary include: (1) some tasks were split into several measures whereas others were not; (2) a statistical trend was given a weight of 0.5; (3) if it was not clear which of the reported doses led to significant effects, it was assumed that the reported effect was applicable to every dose; (4) sometimes two low doses are reported, but they are only weighed once; (5) there was no correction for multiple comparisons for multiple dosing. Finally a major limitation of any review is that studies that did not show significant effects are generally underreported (i.e. publication bias). Therefore, any review is likely to present an overestimation of the reported effects.
In sum, MPH improves working memory and speed of processing and, to a lesser extent, verbal learning and memory, attention and vigilance and reasoning and problem solving in healthy young volunteers. MPH effects are dose-dependent and the dose-response relationship differs between the different cognitive domains. Imaging studies show enhanced attention processing and altered attention-and inhibition-related brain activation. MPH improves cognitive performance in the elderly on tasks of speed of processing, verbal learning and memory and attention and vigilance. MPH effects are, however, considered to be relatively small and MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses the benefit-risk ratio of this specific drug.
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